Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date

Viatris Inc. (NASDAQ:VTRS) is one of the most undervalued stocks under $30 to buy. On February 25, Viatris announced that the ...

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

FDA PDUFA Goal Date Set for October 17, 2026RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, ...
Healio

FDA accepts supplemental NDA for phentolamine in presbyopia

The FDA accepted a supplemental new drug application to expand the indication for Ryzumvi to include the treatment of ...

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for ...
El Adelantado de Segovia

Goodbye to prescription glasses—the FDA approves revolutionary eye drops that improve vision for up to 10 hours a day and could change your routine

Did you know that with the passage of time our sight fails more and more? However, there is a new prescription eye drop approved by the U.S. that promises to ...
Healio

BLOG: If Santa brought us a presbyopia treatment

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. I’ve said it before: There are four stages of life.
Business Insider

FDA Accepts Orasis Pharmaceuticals' New Drug Application for CSF-1 for the Treatment of Presbyopia

- Investigational, novel eye drop candidate was assigned PDUFA goal date of October 22, 2023 PONTE VEDRA, Fla., Feb. 21, 2023 /PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic ...
MarketWatch

Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight

The MarketWatch News Department was not involved in the creation of this content. The launch of emerging therapies, such as LNZ100 by Lenz Therapeutics, Phentolamine Ophthalmic Solution 0.75% by ...
Monthly Prescribing Reference

Vuity Approval Expanded to Allow for Second Dose of Presbyopia Treatment

Vuity contracts the iris sphincter muscle, constricting the pupil to improve near and intermediate visual acuity. The Food and Drug Administration (FDA) has approved the supplemental New Drug ...
MarketWatch

TearOptix Secures Strategic Funding to Transform Presbyopia Treatment and Announces Creation of Scientific Advisory Board

TearOptix, Inc., a pioneering contact lens company developing advanced solutions for patients with presbyopia, today announced the completion of a strategic corporate financing round led by investors ...
Nasdaq

LENZ's Presbyopia Treatment VIZZ Generates $1.6 Mln In Its First Quarter On The Market

(RTTNews) - LENZ Therapeutics, Inc. (LENZ), a pharmaceutical company that recently secured FDA approval for its aceclidine ophthalmic solution VIZZ for presbyopia, has reported preliminary Q4 ...

Viatris Inc.: FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

FDA PDUFA Goal Date Set for October 17, 2026 PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that ...